$PHAS Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PhaseBio Pharmaceuticals Inc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PhaseBio Pharmaceuticals Inc. Get notifications about new insider transactions in PhaseBio Pharmaceuticals Inc for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 04 2021 | PHAS | PhaseBio Pharmaceu ... | Klein Peter Justin | Director | Option Exercise | A | 3.53 | 14,000 | 49,420 | 14,000 | |
| Jun 04 2021 | PHAS | PhaseBio Pharmaceu ... | Loewy Caroline M | Director | Option Exercise | A | 3.53 | 14,000 | 49,420 | 14,000 | |
| Jun 04 2021 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | A | 3.53 | 14,000 | 49,420 | 14,000 | |
| May 24 2021 | PHAS | PhaseBio Pharmaceu ... | York Michael | VP, Corporate Devel ... | Grant | A | 2.80 | 2,897 | 8,112 | 7,059 | 4.2 K to 7.1 K (+69.61 %) |
| May 24 2021 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Grant | A | 2.80 | 5,257 | 14,720 | 23,241 | 18 K to 23.2 K (+29.23 %) |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | A | 4.31 | 234,000 | 1,008,540 | 234,000 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Hanson Kristopher | VP, Head of Legal | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Hanson Kristopher | VP, Head of Legal | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | York Michael | VP, Corporate Devel ... | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | York Michael | VP, Corporate Devel ... | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | Chief Financial Off ... | Option Exercise | A | 4.31 | 76,500 | 329,715 | 76,500 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | Chief Financial Off ... | Option Exercise | A | 4.31 | 76,500 | 329,715 | 76,500 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Lee John Sang | Chief Medical Offic ... | Option Exercise | A | 4.31 | 76,500 | 329,715 | 76,500 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Lee John Sang | Chief Medical Offic ... | Option Exercise | A | 4.31 | 76,500 | 329,715 | 76,500 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Burkhardt Glen | VP, Human Resources | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
| Feb 09 2021 | PHAS | PhaseBio Pharmaceu ... | Burkhardt Glen | VP, Human Resources | Option Exercise | A | 4.31 | 36,000 | 155,160 | 36,000 | |
| Dec 04 2020 | PHAS | PhaseBio Pharmaceu ... | HARRIGAN EDMUND | Director | Buy | P | 4.12 | 6,000 | 24,720 | 6,000 | 0 to 6 K |
| Nov 23 2020 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | Chief Financial Off ... | Grant | A | 3.00 | 1,305 | 3,915 | 41,305 | 40 K to 41.3 K (+3.26 %) |
| Nov 23 2020 | PHAS | PhaseBio Pharmaceu ... | Hanson Kristopher | VP, Head of Legal | Grant | A | 3.00 | 999 | 2,997 | 999 | 0 to 999 |
| Nov 23 2020 | PHAS | PhaseBio Pharmaceu ... | York Michael | VP, Corporate Devel ... | Grant | A | 3.00 | 2,662 | 7,986 | 4,162 | 1.5 K to 4.2 K (+177.47 %) |
| Nov 23 2020 | PHAS | PhaseBio Pharmaceu ... | Ballance David James | VP, Research and Sc ... | Grant | A | 3.00 | 919 | 2,757 | 8,519 | 7.6 K to 8.5 K (+12.09 %) |
| Nov 23 2020 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Grant | A | 3.00 | 4,832 | 14,496 | 17,984 | 13.2 K to 18 K (+36.74 %) |
| Nov 23 2020 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Grant | A | 3.00 | 3,643 | 10,929 | 122,886 | 119.2 K to 122.9 K (+3.06 %) |
| Nov 23 2020 | PHAS | PhaseBio Pharmaceu ... | Burkhardt Glen | VP, Human Resources | Sell | S | 3.45 | 3,497 | 12,065 | 0 | 3.5 K to 0 (-100.00 %) |
| Nov 23 2020 | PHAS | PhaseBio Pharmaceu ... | Burkhardt Glen | VP, Human Resources | Grant | A | 3.00 | 3,497 | 10,491 | 3,497 | 0 to 3.5 K |
| Oct 05 2020 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | M | 1.15 | 5,423 | 6,236 | 0 | |
| Oct 05 2020 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | M | 1.15 | 5,423 | 6,236 | 0 | |
| Oct 05 2020 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Buy | M | 1.15 | 5,423 | 6,236 | 13,152 | 7.7 K to 13.2 K (+70.16 %) |
| Oct 05 2020 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Buy | M | 1.15 | 5,423 | 6,236 | 7,729 | 2.3 K to 7.7 K (+235.17 %) |
| Aug 24 2020 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | M | 1.24 | 10,000 | 12,400 | 148,767 | |
| Aug 24 2020 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Buy | M | 1.24 | 10,000 | 12,400 | 119,243 | 109.2 K to 119.2 K (+9.15 %) |
| Aug 17 2020 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | Chief Financial Off ... | Option Exercise | M | 1.69 | 5,000 | 8,450 | 105,582 | |
| Aug 17 2020 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | Chief Financial Off ... | Buy | M | 1.69 | 5,000 | 8,450 | 40,000 | 35 K to 40 K (+14.29 %) |
| Jun 05 2020 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | A | 4.86 | 16,000 | 77,760 | 16,000 | |
| Jun 05 2020 | PHAS | PhaseBio Pharmaceu ... | Klein Peter Justin | Director | Option Exercise | A | 4.86 | 16,000 | 77,760 | 16,000 | |
| Jun 05 2020 | PHAS | PhaseBio Pharmaceu ... | van den Broek Richard | Director | Option Exercise | A | 4.86 | 16,000 | 77,760 | 16,000 | |
| Jun 05 2020 | PHAS | PhaseBio Pharmaceu ... | Hutson Nancy J | Director | Option Exercise | A | 4.86 | 16,000 | 77,760 | 16,000 | |
| Jun 05 2020 | PHAS | PhaseBio Pharmaceu ... | HARRIGAN EDMUND | Director | Option Exercise | A | 4.86 | 16,000 | 77,760 | 16,000 | |
| Jun 05 2020 | PHAS | PhaseBio Pharmaceu ... | Loewy Caroline M | Director | Option Exercise | A | 0.00 | 16,000 | 0 | 16,000 | |
| Jun 05 2020 | PHAS | PhaseBio Pharmaceu ... | Sapir Alex | Director | Option Exercise | A | 4.86 | 4,909 | 23,858 | 4,909 | |
| Feb 14 2020 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | A | 5.19 | 290,000 | 1,505,100 | 290,000 | |
| Feb 14 2020 | PHAS | PhaseBio Pharmaceu ... | Ballance David James | VP, Research and Sc ... | Option Exercise | A | 5.19 | 55,000 | 285,450 | 55,000 | |
| Feb 14 2020 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | A | 5.19 | 55,000 | 285,450 | 55,000 | |
| Feb 14 2020 | PHAS | PhaseBio Pharmaceu ... | Lee John Sang | Chief Medical Offic ... | Option Exercise | A | 5.19 | 100,000 | 519,000 | 100,000 | |
| Feb 14 2020 | PHAS | PhaseBio Pharmaceu ... | Sapir Alex | Director | Option Exercise | A | 5.19 | 32,000 | 166,080 | 32,000 | |
| Feb 14 2020 | PHAS | PhaseBio Pharmaceu ... | Hanson Kristopher | VP, Head of Legal | Option Exercise | A | 5.19 | 55,000 | 285,450 | 55,000 | |
| Feb 14 2020 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | Chief Financial Off ... | Option Exercise | A | 5.19 | 100,000 | 519,000 | 100,000 | |
| Feb 14 2020 | PHAS | PhaseBio Pharmaceu ... | York Michael | VP, Corporate Devel ... | Option Exercise | A | 5.19 | 55,000 | 285,450 | 55,000 | |
| Feb 14 2020 | PHAS | PhaseBio Pharmaceu ... | Burkhardt Glen | VP, Human Resources | Option Exercise | A | 5.19 | 20,000 | 103,800 | 20,000 | |
| Feb 14 2020 | PHAS | PhaseBio Pharmaceu ... | Burkhardt Glen | VP, Human Resources | Option Exercise | A | 5.19 | 55,000 | 285,450 | 55,000 | |
| Oct 07 2019 | PHAS | PhaseBio Pharmaceu ... | Hanson Kristopher | Vice President, Hea ... | Option Exercise | A | 4.17 | 66,000 | 275,220 | 66,000 | |
| Oct 07 2019 | PHAS | PhaseBio Pharmaceu ... | Hanson Kristopher | Vice President, Hea ... | Option Exercise | A | 4.17 | 66,000 | 275,220 | 66,000 | |
| Sep 10 2019 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | M | 1.24 | 19,000 | 23,560 | 158,767 | |
| Sep 10 2019 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Buy | M | 1.24 | 19,000 | 23,560 | 109,243 | 90.2 K to 109.2 K (+21.05 %) |
| Aug 22 2019 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | CFO and Secretary | Option Exercise | M | 1.44 | 5,000 | 7,200 | 4,038 | |
| Aug 22 2019 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | CFO and Secretary | Option Exercise | M | 1.69 | 10,000 | 16,900 | 110,582 | |
| Aug 22 2019 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | CFO and Secretary | Buy | M | 1.44 | 5,000 | 7,200 | 35,000 | 30 K to 35 K (+16.67 %) |
| Aug 22 2019 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | CFO and Secretary | Buy | M | 1.69 | 10,000 | 16,900 | 30,000 | 20 K to 30 K (+50.00 %) |
| Jul 03 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 459 | 6,426 | 415,959 | 416.4 K to 416 K (-0.11 %) |
| Jul 03 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 255 | 3,570 | 52,397 | 52.7 K to 52.4 K (-0.48 %) |
| Jul 03 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 180 | 2,520 | 162,890 | 163.1 K to 162.9 K (-0.11 %) |
| Jul 03 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 2,014 | 28,196 | 1,818,638 | 1.8 M to 1.8 M (-0.11 %) |
| Jun 20 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 63 | 882 | 416,418 | 416.5 K to 416.4 K (-0.02 %) |
| Jun 20 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 35 | 490 | 52,655 | 52.7 K to 52.7 K (-0.07 %) |
| Jun 20 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 25 | 350 | 163,074 | 163.1 K to 163.1 K (-0.02 %) |
| Jun 20 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Sell | S | 14.00 | 277 | 3,878 | 1,820,656 | 1.8 M to 1.8 M (-0.02 %) |
| May 24 2019 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | CFO and Secretary | Option Exercise | M | 1.69 | 15,000 | 25,350 | 120,582 | |
| May 24 2019 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | CFO and Secretary | Buy | M | 1.69 | 15,000 | 25,350 | 20,000 | 5 K to 20 K (+300.00 %) |
| May 21 2019 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | M | 1.24 | 19,131 | 23,722 | 0 | |
| May 21 2019 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | M | 2.27 | 19,913 | 45,203 | 0 | |
| May 21 2019 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Buy | M | 1.24 | 19,131 | 23,722 | 90,243 | 71.1 K to 90.2 K (+26.90 %) |
| May 21 2019 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Buy | M | 2.27 | 19,913 | 45,203 | 71,112 | 51.2 K to 71.1 K (+38.89 %) |
| May 13 2019 | PHAS | PhaseBio Pharmaceu ... | Mukhopadhyay Bibhash | Director | Option Exercise | A | 13.23 | 11,000 | 145,530 | 11,000 | |
| May 13 2019 | PHAS | PhaseBio Pharmaceu ... | Mukhopadhyay Bibhash | Director | Option Exercise | A | 13.23 | 11,000 | 145,530 | 11,000 | |
| May 13 2019 | PHAS | PhaseBio Pharmaceu ... | Klein Peter Justin | Director | Option Exercise | A | 13.23 | 11,000 | 145,530 | 11,000 | |
| May 13 2019 | PHAS | PhaseBio Pharmaceu ... | van den Broek Richard | Director | Option Exercise | A | 13.23 | 2,750 | 36,383 | 2,750 | |
| May 13 2019 | PHAS | PhaseBio Pharmaceu ... | HARRIGAN EDMUND | Director | Option Exercise | A | 13.23 | 4,583 | 60,633 | 4,583 | |
| May 13 2019 | PHAS | PhaseBio Pharmaceu ... | Loewy Caroline M | Director | Option Exercise | A | 13.23 | 9,167 | 121,279 | 9,167 | |
| May 13 2019 | PHAS | PhaseBio Pharmaceu ... | Hutson Nancy J | Director | Option Exercise | A | 13.23 | 11,000 | 145,530 | 11,000 | |
| May 13 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | A | 13.23 | 11,000 | 145,530 | 11,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | A | 3.15 | 36,000 | 113,400 | 36,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | York Michael | VP, Corporate Devel ... | Option Exercise | A | 3.15 | 45,000 | 141,750 | 45,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | van den Broek Richard | Director | Option Exercise | A | 3.15 | 23,000 | 72,450 | 23,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | van den Broek Richard | Director | Option Exercise | A | 3.15 | 22,000 | 69,300 | 22,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Option Exercise | A | 3.15 | 36,000 | 113,400 | 36,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | CFO and Secretary | Option Exercise | A | 3.15 | 100,000 | 315,000 | 100,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Loewy Caroline M | Director | Option Exercise | A | 3.15 | 8,900 | 28,035 | 8,900 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Klein Peter Justin | Director | Option Exercise | A | 3.15 | 36,000 | 113,400 | 36,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Klein Peter Justin | Director | Option Exercise | A | 3.15 | 36,000 | 113,400 | 36,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Hutson Nancy J | Director | Option Exercise | A | 3.15 | 8,900 | 28,035 | 8,900 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Hutson Nancy J | Director | Option Exercise | A | 3.15 | 8,900 | 28,035 | 8,900 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Ballance David James | VP, Research and Sc ... | Option Exercise | A | 3.15 | 45,000 | 141,750 | 45,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Ballance David James | VP, Research and Sc ... | Option Exercise | A | 3.15 | 45,000 | 141,750 | 45,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | A | 3.15 | 45,000 | 141,750 | 45,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Arnold Susan Elizabeth | VP, Preclinical and ... | Option Exercise | A | 3.15 | 45,000 | 141,750 | 45,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | A | 3.15 | 263,000 | 828,450 | 263,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Option Exercise | A | 3.15 | 263,000 | 828,450 | 263,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Mukhopadhyay Bibhash | Director | Option Exercise | A | 3.15 | 36,000 | 113,400 | 36,000 | |
| Mar 01 2019 | PHAS | PhaseBio Pharmaceu ... | Mukhopadhyay Bibhash | Director | Option Exercise | A | 3.15 | 36,000 | 113,400 | 36,000 | |
| Dec 17 2018 | PHAS | PhaseBio Pharmaceu ... | HARRIGAN EDMUND | Director | Option Exercise | A | 3.65 | 68,966 | 251,726 | 68,966 | |
| Dec 17 2018 | PHAS | PhaseBio Pharmaceu ... | Ballance David James | VP, Research and Sc ... | Buy | P | 3.94 | 1,000 | 3,940 | 7,600 | 6.6 K to 7.6 K (+15.15 %) |
| Dec 17 2018 | PHAS | PhaseBio Pharmaceu ... | Hutson Nancy J | Director | Buy | P | 4.46 | 1,000 | 4,460 | 1,000 | 0 to 1,000 |
| Dec 17 2018 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Buy | P | 3.69 | 1,000 | 3,690 | 51,199 | 50.2 K to 51.2 K (+1.99 %) |
| Dec 11 2018 | PHAS | PhaseBio Pharmaceu ... | York Michael | VP, Corporate Devel ... | Buy | P | 3.88 | 1,500 | 5,820 | 1,500 | 0 to 1.5 K |
| Dec 11 2018 | PHAS | PhaseBio Pharmaceu ... | Sharp John P | CFO and Secretary | Buy | P | 3.84 | 5,000 | 19,200 | 5,000 | 0 to 5 K |
| Dec 11 2018 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Buy | P | 3.85 | 800 | 3,080 | 51,699 | 50.9 K to 51.7 K (+1.57 %) |
| Dec 11 2018 | PHAS | PhaseBio Pharmaceu ... | Mow Jonathan P | Chief Executive Off ... | Buy | P | 3.88 | 2,200 | 8,536 | 50,899 | 48.7 K to 50.9 K (+4.52 %) |
| Dec 06 2018 | PHAS | PhaseBio Pharmaceu ... | Thorp Clay | Director | Buy | P | 3.13 | 4,000 | 12,520 | 15,799 | 11.8 K to 15.8 K (+33.90 %) |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Klein Peter Justin | Director | Option Exercise | C | 0.00 | 2,303 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Klein Peter Justin | Director | Option Exercise | S | 0.00 | 3 | 0 | 2,303 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Klein Peter Justin | Director | Option Exercise | X | 0.00 | 103 | 0 | 2,306 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Klein Peter Justin | Director | Option Exercise | X | 0.12 | 103 | 12 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | Klein Peter Justin | Director | Buy | C | 0.00 | 2,303 | 0 | 2,303 | 0 to 2.3 K |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | C | 0.00 | 1,124,301 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | C | 0.00 | 437,706 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | S | 0.00 | 4,349 | 0 | 437,706 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | X | 0.00 | 181,190 | 0 | 442,055 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | X | 0.12 | 181,190 | 21,743 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | C | 0.00 | 3,279,627 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | S | 0.00 | 1,177 | 0 | 3,279,627 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | X | 0.00 | 49,030 | 0 | 3,280,804 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Option Exercise | X | 0.12 | 49,030 | 5,884 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Buy | P | 5.00 | 1,800,000 | 9,000,000 | 6,641,634 | 4.8 M to 6.6 M (+37.18 %) |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | NEW ENTERPRISE ASSOCIATES 13 L ... | 10% Owner | Buy | C | 0.00 | 4,841,634 | 0 | 4,841,634 | 0 to 4.8 M |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 30,334 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 6,413 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 63,688 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 22,452 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 4,746 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 47,140 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 165,395 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 34,968 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 347,250 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 56,874 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 12,025 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | C | 0.00 | 119,408 | 0 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | S | 0.00 | 113 | 0 | 22,452 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.00 | 4,690 | 0 | 22,565 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.12 | 4,690 | 563 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | S | 0.00 | 24 | 0 | 4,746 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.00 | 991 | 0 | 4,770 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.12 | 991 | 119 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | S | 0.00 | 237 | 0 | 47,140 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.00 | 9,847 | 0 | 47,377 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.12 | 9,847 | 1,182 | 0 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | S | 0.00 | 81 | 0 | 165,395 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.00 | 3,359 | 0 | 165,476 | |
| Oct 24 2018 | PHAS | PhaseBio Pharmaceu ... | TUFTS LINDA | Director | Option Exercise | M | 0.12 | 3,359 | 403 | 0 |